- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07600814
Pain Induced by m-Cresol as Preservative
Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers
Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.
This study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Background and Objective:
m-Cresol has been used since 1980 to limit bacterial growth in parenteral medications. Although it is generally considered safe, evidence for local side effects has appeared in case reports and a clinical trial where changing the preservative led to a disappearance of local discomfort. This suggests that the preservative itself, rather than the active drug or the pH of the solution, may be responsible for a pain sensation. The objective of this study is to systematically evaluate if subcutaneous injection of m-Cresol at clinically relevant concentrations causes pain in humans.
Study Design:
This is a randomized, double-blind, placebo-controlled, 3-period crossover trial in healthy volunteers (n=18). To ensure an unbiased assessment and control for potential order effects, a Williams balanced design is utilized for the randomization of treatment sequences.
Methodology:
Familiarization: Participants first receive an unblinded injection of control solution to become accustomed to the experimental procedure and the numerical pain rating scale.
Interventions: Subjects receive three randomized, double-blind 300 µl subcutaneous injections at different spots on a belly fold, separated by at least 3 cm. The treatments include:
- m-Cresol at 0.1%
- m-Cresol at 0.25%
- Control solution. Pain Assessment: For each injection, pain intensity is recorded every 5 seconds using a numerical pain rating scale (0-100) until no pain is reported for 30 consecutive seconds. The pain caused by the needle insertion itself is rated separately before the injection begins to serve as a covariate for the statistical analysis.
Statistical Analysis:
The primary endpoint is the Area Under the Curve (AUC) of the subjective pain ratings over time. Comparisons will be made between the different m-Cresol concentrations and the vehicle control using a linear mixed model to test the primary hypotheses.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Felix J. Resch
- Telefonnummer: +43 1 40160 31419
- E-mail: felix.resch@meduniwien.ac.at
Undersøgelse Kontakt Backup
- Navn: Michael J.M. Fischer
- Telefonnummer: +43 1 40160 31410
- E-mail: michael.jm.fischer@meduniwien.ac.at
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion criteria
- Age between 18 and 70 years
- Full legal capacity Exclusion criteria
- Participant of another study, ongoing or within the last four weeks
- Current medication intake (except hormonal contraception) or drug abuse
- Female subjects: Positive pregnancy test or breastfeeding
- Body temperature above 38°C, verified by infrared thermometer
- Known allergic diseases, in particular asthmatic disorders and skin diseases
- Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: m-Cresol 0.1%
Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.1%.
|
A preservative administered subcutaneously at 0.1%, a common concentration used in medicines.
|
|
Eksperimentel: m-Cresol 0.25%
Participants receive a 300 µl subcutaneous injection of m-Cresol at a concentration of 0.25%.
|
A preservative administered subcutaneously at 0.25%, a common concentration used in medicines.
|
|
Placebo komparator: Control solution
Participants receive a 300 µl subcutaneous injection of control solution.
|
A control solution administered subcutaneously.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area Under the Curve (AUC) of Pain Intensity
Tidsramme: From injection start until pain subsides (approximately 15-60 seconds per injection).
|
Total pain burden calculated as the Area Under the Curve of serial pain ratings (0-100 numerical pain rating scale) recorded every 5 seconds from the start of injection until no pain is reported for 30 seconds.
|
From injection start until pain subsides (approximately 15-60 seconds per injection).
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Michael J.M. Fischer, Medical University of Vienna
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- EK1688/2024
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Smerte
-
Istanbul University - CerrahpasaRekrutteringPatellofemoral Pain, PfpTyrkiet (Türkiye)
-
Pamukkale UniversityIkke rekrutterer endnuPatellofemoral Pain, PfpTyrkiet (Türkiye)
-
Beijing Sport UniversityAfsluttetPatellofemoral Pain, PfpKina
-
Beijing Sport UniversityIkke rekrutterer endnuPatellofemoral Pain, Pfp
-
Beijing Sport UniversityIkke rekrutterer endnu
-
Sahmyook UniversityAfsluttetMyofascial Pain Syndrome (MPS)Sydkorea
-
Future University in EgyptAfsluttet
-
Camilo Jose Cela UniversityAfsluttetMyofascial Pain Syndrome (MPS)Spanien
-
Izmir Tinaztepe UniversityEge UniversityIkke rekrutterer endnuRygliggende stilling | FLACC Skala | Behavioral Pain Scale
-
University of California, DavisNational Institutes of Health (NIH); National Center for Complementary...Ikke rekrutterer endnuKronisk lænderygsmerter (cLBP) | Myofascial Pain Syndrome (MPS)Forenede Stater
Kliniske forsøg med m-Cresol 0.1%
-
Medical University of SilesiaPH DOCTOR N&D Wiśniewscy S.K.A.AfsluttetHudældning | FotoaldringPolen
-
Mayo ClinicTilmelding efter invitation
-
Research Institute of Virology, Ministry of Health...AfsluttetPatienter med COVID-19Usbekistan
-
Shenzhen People's HospitalRekruttering
-
Universitaire Ziekenhuizen KU LeuvenAfsluttetSund og rask | Mavetømning | MotilitetsforstyrrelseBelgien
-
Hospital Clinic of BarcelonaRekrutteringSvaghed i øvre lemmer på grund af central neurologisk skade | Iskaemisk apopleksiSpanien
-
Merck Sharp & Dohme LLCAfsluttetMæslinger | Røde hunde | Fåresyge | VaricellaFrankrig, Italien
-
Tulane UniversityRekrutteringDepression | AngstForenede Stater
-
Samueli Institute for Information BiologyWilliam Beaumont Army Medical Center; Palmer Center for Chiropractic Research... og andre samarbejdspartnereUkendt
-
RDC Clinical Pty LtdLallemand Bio-IngredientsAfsluttetAllergisk rhinitis på grund af græspollenAustralien